UK: Health secretary asks competition watchdog to look at drug pricing

The health secretary, Jeremy Hunt, has asked the competition watchdog to look at claims that drug companies are exploiting the NHS to raise the price of medicines.

Hunt called in the Competition and Markets Authority (CMA) after aninvestigation by the Times suggested that prices have been vastly increased as the result of a loophole in NHS rules.

A health department spokesman said: “These are serious allegations and no pharmaceutical company should be exploiting the NHS. The secretary of state has asked the CMA to urgently look at the evidence uncovered by the Times as part of their continuing investigations into excessive drugs pricing.”

The Times investigation suggests suppliers are able to introduce “extortionate” price rises by dropping the brand name and taking the medicines outside NHS profit controls. The Times says the companies face limited competition on long-established, off-patent drugs, which they bought from large pharmaceutical companies. They allege that wholesalers and their customers also receive a cut and that the prices of 32 drugs have risen by more than 1,000% in the past five years.

The CMA can impose tough financial penalties on a company that is found to have charged excessive prices. The health department can recover losses through the courts.

Full Content: The Guardian

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.